长春瑞滨持续泵入联合表柔吡星治疗紫杉类耐药乳腺癌的临床研究  

Clinical Research of Continuous Intravenous Pumping of Vinorelbine (NVB) Combined with Epirubicin (EPI) in the Treatment of Paclitaxel-resistant Breast Cancer

作　　者：杨艳[1] 王光明[1] 王晓明[1] 王洪燕[1] 方晓敏[1] 

机构地区：[1]威海市立医院,山东威海264200

出　　处：《世界中西医结合杂志》2012年第8期685-687,共3页World Journal of Integrated Traditional and Western Medicine

基　　金：威海市科技发展计划项目(No.2010-3-86-5)

摘　　要：目的探讨长春瑞滨持续静脉泵入联合表柔吡星治疗紫杉醇类药物耐药的乳腺癌的临床疗效和毒性反应。方法治疗组36例,分别在第1天和第8天静脉泵维持静脉滴注长春瑞滨120 h;对照组36例,分别在第1天和第8天静脉滴注长春瑞滨30 min。两组患者应用长春瑞滨前后静脉滴注地塞米松5 mg,减少长春瑞滨对静脉的刺激;同时两组患者均在第1天联合表柔吡星静脉滴注,21 d为1个周期,至少用2个周期评价疗效。结果治疗组完全缓解(CR)的比例明显高于对照组,差异有统计学意义(P<0.05),而部分缓解(PR)、进展(SD)、稳定(PD)两组比较,差异均无统计学意义(P>0.05)。两组患者的不良反应:治疗组患者白细胞减少、静脉炎、周围神经毒性、恶心、呕吐等不良反应明显少于对照组,差异有统计学意义(P<0.01)。结论长春瑞滨持续静脉泵入联合表柔吡星治疗紫杉醇类药物耐药的乳腺癌的临床效果较为明显,值得临床进一步推广。Objective To explore the clinical efficacy and toxic reaction of the continuous intrave nous pumping of vinorelbine （ NVB ） combined with epirubiein （ EPI ） in the treatment of paclitaxel resistant breast cancer. Methods For 36 cases in a treatment group,on the 1atand 8th days,the continuous intrave nous drip of NVB with intravenous pumping was provided for 120 h. For 36 cases in a control group, on the 1 st and 8th days ,the intravenous drip of NVB was provided for 30 h. In each group, before and after NVB infu sion, dexamethasone （DXM）was administered for intravenous drip,5 mg to reduce the intravenous stimulation of NVB. At the same time, EPI intravenous drip was combined on the l st day for the patients in each group. The treatment of 21 days made 1 period. The efficacy was evaluated after treatment for at least 2 periods. Re suits In the treatment group, the proportion of complete response（CR） was higher apparently than that in the control group, presenting the statistical significant difference （ P 〈 0.05 ）. The differences in the proportions of partial response（PR）, stable disease （SD）and progressive disease （PD）were not significant statistically in comparison between two groups（ P 〉 0.05 ）. Concerning the adverse reactions for the patients in two groups, the eases of leucopenla, phlebitis, peripheral neurotoxieity, nausea, vomiting and the others in the treatment group were obviously less than those in the control group, presenting the statistical significant differences （ P 〈 0. 01 ）. Conclusion The continuous intravenous pumping of NVB combined with EPI achieves the apparent clinical efficacy in the treatment of paclitaxel resistant breast cancer. Hence, this therapeutic program de serves to be promoted in clinic.

关 键 词：长春瑞滨 紫杉醇 乳腺癌 持续静脉泵入 

分 类 号：R730.53[医药卫生—肿瘤] R73[医药卫生—临床医学]